MVA-BN as monkeypox vaccine for healthy and immunocompromised

• E.T. Overton,
• S. Lawrence,
• J. Stapleton,
• H. Weidenthaler,
• D. Schmidt,
• K. Nopora,
• T. Meyer,
• J. Maclennan,
• B. Koenen,
• G. Silbernagl,
• A. Volkmann,
• P. Chaplin

Affiliations

E.T. Overton

University of Alabama, Division of Infectious Diseases, Birmingham, United States

S. Lawrence

Washington University School of Medicine, Division of Infectious Diseases, St. Louis, United States

J. Stapleton

University of Iowa, Division of Infectious Diseases, Iowa City, United States

H. Weidenthaler

Bavarian Nordic, Clinical Development, Martinsried, Germany

D. Schmidt

Bavarian Nordic, QC Development, Martinsried, Germany

K. Nopora

Bavarian Nordic, Clinical Development, Martinsried, Germany

T. Meyer

Bavarian Nordic, Clinical Development, Martinsried, Germany; Corresponding author.

J. Maclennan

Bavarian Nordic, Clinical Development, Martinsried, Germany

B. Koenen

Bavarian Nordic, QC Development, Martinsried, Germany

G. Silbernagl

Bavarian Nordic, Clinical Development, Martinsried, Germany

A. Volkmann

Bavarian Nordic, Early Development, Martinsried, Germany

P. Chaplin

Bavarian Nordic, Executive Management, Kvistgard, Denmark